WHO WE ARE
Eos Biosciences, Inc. is a Nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology to facilitate the effective delivery of approved and novel therapeutics to disease sites.
The company’s most advanced programs are oncology-focused. Eos also has several programs under development, including targeting therapeutics across the blood brain barrier and packaging and delivery of nucleic acid therapeutics.
Eos Biosciences will attend the 2018 Biotechnology Innovation Organization (BIO) International Convention in Boston, June 2-5, 2018
Eos Biosciences will attend the 2018 Biotechnology Innovation Organization (BIO) International Convention being held June 2-5, 2018, in Boston. Eos Biosciences’ Chief Executive Officer, Omar Haffar, Ph.D. and Chief Financial Officer, Thomas Plotts will attend the BIO International Convention.
Los Angeles, CA- October 17, 2017- Eos Biosciences, Inc., a bio-targeted nanomedicines company developing a novel nanobiologic particle drug delivery platform technology (Eosomes), and a proprietary oncology-specific product pipeline, announced that the U.S. Patent and Trademark Office has now issued Eos Biosciences a second patent, U.S. Patent No. 9,789,201, for [...]
Eos Biosciences announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,757,386, which covers composition of matter and method of use for Eos Biosciences’ theranostic product Eos-002, a HER3-targeted Eosome with manganese corrole payload. HER3 is over-expressed on many types of metastatic and drug-resistant solid tumors.